Quan Zhang1,2, Ting Zhang1,3, Hong Zhuang1,3, Zhongcui Sun1,3, Yaowu Qin4,5. 1. EENT Hospital, Fudan University, Shanghai, China. 2. Hainan (Boao) International Eye Hospital, Hainan, China. 3. Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, China. 4. EENT Hospital, Fudan University, Shanghai, China, qinyaowu715@126.com. 5. Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, China, qinyaowu715@126.com.
Abstract
PURPOSE: This study evaluates the efficacy and patient satisfaction of intravitreal conbercept (IVC) as adjunctive treatment before panretinal photocoagulation (PRP) for Chinese proliferative diabetic retinopathy (PDR) with or without clinically significant macular edema. METHODS: We enrolled 94 patients and categorized them into 2 groups: eyes that received PRP with single-dose IVC (0.5 mg/0.05 mL) 1 week before PRP (Plus group) or PRP only (PRP group). We measured the central macular thickness (CMT) by optical coherence tomography and best-corrected visual acuity. Satisfaction of PRP after 3 months was evaluated by a satisfaction questionnaire. RESULTS: Single-dose IVC 1 week before PRP significantly increased the PRP completion rate and satisfaction of treatment after 3 months in PDR patients. The average CMT significantly decreased in the Plus group but increased in the PRP group. No average visual changes were detected in the Plus group, but significant average visual loss was detected in the PPR group. The most important factors that determined satisfaction were the PRP completion rate in the short term and better vision gain after PRP. CONCLUSIONS: IVC is a promising adjunctive treatment to PRP in the treatment of PDR. Single-dose IVC 1 week before PRP was suggested to improve PRP completion rate and patient satisfaction in the short term.
PURPOSE: This study evaluates the efficacy and patient satisfaction of intravitreal conbercept (IVC) as adjunctive treatment before panretinal photocoagulation (PRP) for Chinese proliferative diabetic retinopathy (PDR) with or without clinically significant macular edema. METHODS: We enrolled 94 patients and categorized them into 2 groups: eyes that received PRP with single-dose IVC (0.5 mg/0.05 mL) 1 week before PRP (Plus group) or PRP only (PRP group). We measured the central macular thickness (CMT) by optical coherence tomography and best-corrected visual acuity. Satisfaction of PRP after 3 months was evaluated by a satisfaction questionnaire. RESULTS: Single-dose IVC 1 week before PRP significantly increased the PRP completion rate and satisfaction of treatment after 3 months in PDR patients. The average CMT significantly decreased in the Plus group but increased in the PRP group. No average visual changes were detected in the Plus group, but significant average visual loss was detected in the PPR group. The most important factors that determined satisfaction were the PRP completion rate in the short term and better vision gain after PRP. CONCLUSIONS: IVC is a promising adjunctive treatment to PRP in the treatment of PDR. Single-dose IVC 1 week before PRP was suggested to improve PRP completion rate and patient satisfaction in the short term.